Sheet 1 of 2

		#				1 20045	+ 316		LADO		TION N	<u> </u>
FORM PTE 1449			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY, DOCKET NO.:			APPLICATION NO.: 10/776, 988			
PATENT AND TRADEMAR RADEMINFORMATION DISCLOSURE STATEM						OC01617K1			107770, 300			
	INF	ORN			EMENI	Timothy J. Guzi et al.						
l			BY APPLIC									
(Use several sheets if necessary)					FILING DATE:			GROUP LY.				
		- (0										
			•	U.S. PAT	ENT DOCU	MENTS						
	*EXAMINER		DOCUMENT	DATE	N/	ME	CLASS				FILING DATE	
INIT		 	NUMBER	44/05/4005	0.00	O'llhan and all		 		<u> 455</u>	APPROPRIATE	
	4	IAA	5,571,813	11/05/1996		er et al.	₩	+-	 	₩		
	+	AB	5,602,136	02/11/1997		er et al.	╁	+-		 		
	-	AC	5,602,137	02/11/1997		er et al.	┼	+-		├—	ļ.,	
·		AD	5,688,949	11/18/1997		e et al.	┿	 	-		ļ	
	+	AE	5,707,997	01/13/1998		i et al.	╁	├	 	 		
		AF	5,919,815	07/06/1999		ey et al.	╀-	 	ļ	<u> </u>		
	4—	AG	6,040,321	03/21/2000		et al.	╀		-			
	↓	AH	6,107,305	08/22/2000		a et al.	₩					
	↓ _	AL	6,191,131	02/20/2001		et al.	╄	ļ	 	<u> </u>		
	₩_	AJ	6,262,096	07/17/2001		et al.	ـــ	-	-	\vdash		
		AK	6,413,974	07/02/2002	Dumo	nt et al.	<u> </u>	_	Ц.		L	
			F	FOREIGN PA	ATENT DOC	CUMENTS						
		Ι'''	DOCUMENT	DATE	COUNTRY	······································	TCL	ASS	SUE	3-	TRANS	LATION
			NUMBER		•				CL	SS	YES	NO
_	7	AL	DE 102 23 917 A1	11/12/2003	Ger	many	1					
		AM	EP 0 628 559	04/03/2002	Eu	rope						
	1	AN	EP 1 334 973	08/13/2003	Eu	rope						
		AO	WO 02/22610	03/21/2002		CT	1					
		AP	WO 02/40485	05/23/2002	P	CT.	·		1			
		AQ	WO 02/50079	06/27/2002	. P	CT ·						
	IZ	AR	WO 03/091256 A1	11/06/2003	P	CT						
	<i>y</i>	AS	WO 95/35298	12/28/1995	P	CT						
		OT	HER DOCUMENT	S (Including	Author Title	e Date Pert	ine	at Pa	mas	Et.	C)	
		AT										
AT Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", (1994), 224: 771-786.								, 20	7. J.	Diocilai	"	
-		AU	Kim et al., Discover		zale labibitore	of Cyclin-Deper	nden	l Kins	150 2	· Swr	thosis	Y-5314
1			Crystallographic Ana									
1	•]	3905-3927.		ogical Activities	, Journal or IVI	00101	a, Om	<i>311113</i> 1	· y. (*	2002), 4	.
		AV	Mettey et al., "Aloisir	es, a New Far	nily of CDK/GS	K-3 Inhibitors	SAF	Stu	dv C	rvsta	1 Struct	ure in
			Complex with CDK2									
1			236.	,,					,,,,,	,	-/-	,,
		AW										
ı			a]pyrimidines", J. Med. Chem. (1977), 20(2): 296-299.									
		AX	Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent									
	Kinase Inhibitor, in Patients with Refractory Neoplasms", Journal of Clinical Oncology (Septemb											
	1998), 16(9): 2986-2999.											
U		AY	Meijer et al., "Bioche	mical and Cell	ular Effects of	Roscovitine, a f	Pote	nt and	d Sel	ectiv	e Inhibi	or of
the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", Eur. J. Biochem. (1997), 243:527-538.												
EXAMINER // / / / DATE CONSIDERED												
10m 14c Vbs 6/17/67												
	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to											
annlic	ni Cili	311011	ii iiut iii contormatyce	and not consid	iereo. Inciude	copy or this for	n Wi	m ne	KI CO	untiU	meauor	. (0
שוועקב	applicant.											

FORM PTO	-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY, DOCKET NO.:	APPLICATION NO.:							
			OC01617K1 10/776,988 APPLICANT:								
INFO	JKM	IATION DISCLOSURE STATEMENT BY APPLICANT	Timothy J. Guzi et al.								
	(U	se several sheets if necessary)	FILING DATE: 02/22/2004	GROUP:							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
AZ Bible et al., "Cytotoxic Synergy Between Flavopindol (NSC 649890, L86-8275) and Vario Antineoplastic Agents: The Importance of Sequence of Administration", Cancer Researc 15, 1997), 57: 3375-3380.											
	ВА	Shiota et al., "Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5-α]pyrimidine Derivatives", Chem. Pharm. Bull. (1999), 47(7): 928-938.									
	BB	Translation of WO 03/91256, A Rising Sun Communications Ltd. Translation Product, (1-62)									
	BC	Yasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted									
1 1		Pyrazolo[1,5-a]pyrimidines.*, Chem. Pharm. Bull (1962), 10: 620-626.									
	BD	Cai et al., "5-(N-Oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: Novel, Systemically Active and Broad Spectrum Antagonists for NMDA/glycine, AMPA, and Kainate Receptors", J. Med. Chem. (1997), 40:3679-3686.									
	BE	Bruce L. Finkelstein, "Regioselective Lithiation and Reaction of [1,2,4]Triazolo[1,5-a]pyridine and Pyrazolo[1,5-a]pyridine", J. Org. Chem., (1992), 57: 5538-5540.									
	BF	Ongkeko et al., "Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage", Journal of Cell Science (1995), 108: 2897-2904.									
	BG										
W	BH Novinson et al., "Synthesis and Antimicrobial Activity of Some Novel Heterocycles. Azolo-αs-triazines ¹ ", Journal of Medicinal Chemistry, (1976), 19(4): 517-520.										
	ВІ		, ,								
EXAMINER // / DATE CONSIDERED /											
10m/1/c/											
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line											
through cita	through citation if not in conformance and not considered. Include copy of this form with next communication to										